New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.

Opioid use in pregnancy can lead to several complications, among which are poor fetal growth, preterm birth, maternal death, and neonatal abstinence syndrome. Additionally, the long-term effects of prenatal opioid exposure are not well known. The main treatment option for opioid use disorder in pregnant patients has historically been methadone, however, new evidence suggests that buprenorphine may be an appropriate and safe alternative for both the mother and baby. There are many individual reasons why patients may be better candidates for one therapy or another, and these reasons hold true during pregnancy. This presentation focuses on discussing the evidence behind using either methadone or buprenorphine for the treatment of opioid use disorder in pregnant patients, and situations that may guide medication choice.